This joint effort led by Boehringer Ingelheim’s Research Beyond Borders (RBB) Unit focuses on pre-clinical testing of Exogenus Therapeutics’s lead candidate, Exo-101, in various regenerative medicine indications. The collaboration will expand our previous pre-clinical studies and provide new insights on the therapeutic potential of these natural EVs. This recent partnership is perfectly aligned with Exogenus Therapeutics mission to foster a new era of extracellular vesicle-based solutions to solve major healthcare challenges, through internal and collaborative R&D.